An arrhythmia is a problem with the speed or rhythm of the heartbeat. During an arrhythmia, the heart can beat too fast, too slow, or with an irregular rhythm. A heartbeat that is too fast is called tachycardia. A heartbeat that is too slow is called bradycardia. Most arrhythmias are harmless, but some can be serious or even life threatening. When the heart rate is too slow, too fast, or irregular, the heart may not be able to pump enough blood to the body. Lack of blood flow can damage the brain, heart, and other organs.
Medtronic, Inc. today announced data from the STOP AF (Sustained Treatment of Paroxysmal Atrial Fibrillation) clinical trial during late-breaking sessions at the 59th Annual Scientific Session of the American College of Cardiology in Atlanta. The data showed superiority over anti-arrhythmic drugs, with 69.9 percent of patients with paroxysmal atrial fibrillation (PAF) treated with the Arctic Front® Cardiac CryoAblation Catheter System remaining free of atrial fibrillation (AF) one year after cryoablation, compared to 7.3 percent on drug therapy.
St. Jude Medical, Inc. today announced it will display products and technologies from the company’s wide array of clinical solutions in the cardiology, cardiac surgery, atrial fibrillation and cardiac rhythm management markets at ACC 2010.
Current drugs used to treat heart failure and arrhythmias (irregular heartbeat) have limited effectiveness and have side effects. New basic science findings from a University of Iowa study suggest a way that treatments could potentially be refined so that they work better and target only key heart-related mechanisms.
To get life-threatening diseases under control, patients in the intensive care unit usually are administered many medications at the same time. Even for experts, it is difficult to keep track of the variety of possible side effects and interactions.
According to Millennium Research Group, the global authority on medical technology market intelligence, the recent launch of irrigated-tip catheters into the Japanese market will drive the ablation catheter market by a compound annual growth rate of approximately 15% through 2014.
Responding to the cardiac CT market’s need for superior image quality with lower radiation doses, Toshiba America Medical Systems, Inc., has unveiled new cardiac software enhancements available now for the Aquilion® ONE and Aquilion Premium CT systems. The new cardiac CT software package is designed to reduce radiation exposure while maintaining outstanding image quality.
2009 was an eventful year, with a mixture of successes and breakthroughs, but also with some challenges which required that measures be taken during the autumn. Our mature clinics continued to develop well during the year, as did most of our newly started clinics. 2009 was therefore the first time that we achieved a positive whole-year result before close-down costs in England, despite increasing development and start-up costs for the Group as a whole.
London Genetics Limited, an expert in the use of pharmacogenetics in clinical drug discovery and development, has awarded the first three grants from its proof-of-concept (POC) fund. The awards, to teams at Imperial College London and University College London, are for research in the areas of immunotherapy, schizophrenia and heart disease.
NewCardio, Inc., a cardiac diagnostic technology provider, announced today that the Heart Rhythm Society (HRS) has accepted an abstract detailing the superior performance of NewCardio's patented CardioBip™ technology for remote wireless monitoring and detection of atrial fibrillation (AF). The study results, which discuss the use of CardioBip for improved AF monitoring and detection, are scheduled for oral presentation at the Heart Rhythm Society 31st Annual Scientific Sessions, May 12-15, 2010, in Denver, Colorado.
Atrial fibrillation is a cardiac arrhythmia - a chronic irregularity of heartbeat - which affects an estimated 1 million people in Germany. Although the condition is not acutely life-threatening, it does increase the risk of developing more serious illnesses, such as cardiac insufficiency, stroke and dementia. In the third of a series of genomewide asssociation studies, an international team of researchers, led by LMU physician PD Dr. Stefan K--b, now reports the identification of a new gene locus that has a significant influence on risk for atrial fibrillation.
An international research team has identified a common gene variant associated with a form of the irregular heartbeat called atrial fibrillation. In their report in the journal Nature Genetics, being published online, the investigators describe finding that variations affecting a protein that may help control the heart's electrical activity appear to increase the risk of what is called lone atrial fibrillation (AF), a type seen in younger individuals with no other form of heart disease.
Scientists are reporting the first-ever data to show that the enzyme calcineurin is critical in controlling normal development and function of heart cells, and that loss of the protein leads to heart problems and death in genetically modified mice.
Stereotaxis announced that the recent BBC documentary "From the Heart" included a cardiac ablation procedure performed with the Stereotaxis System by Dr. Muchtiar Khan of OLVG Hospital in Amsterdam. The program's second half, beginning at 10:30 of the 25-minute run time, features extensive scenes from the Stereotaxis procedure.
Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.
“The Meda Group expects to achieve sales of about SEK 13,000 million and an EBITDA of about SEK 4,200 million for full-year 2009.”
Next month, in the Norwegian town of Rena, 12,000 elite cross-country skiers will line up for this year's Birkebeiner ski marathon, an annual endurance race which will take them through 54 kilometres of snow-covered countryside to the winter sports resort of Lillehammer.
Bioheart, Inc., announced today that the company has commenced work on its REGEN trial, a Phase I Clinical Trial to test genetically modified MyoCell® in patients suffering from Congestive Heart Failure (CHF). Bioheart’s MyoCell® is a regenerative cell therapy that uses myoblasts, or muscle stem cells,that are grown from a patient’s own muscle. MyoCell® has been tested successfully on patients in four clinical trials.
CardioNet, Inc. announced today that the 300,000th patient has been monitored with the Company’s Mobile Cardiac Outpatient Telemetry (MCOT™) service. MCOT is the first system to provide real-time wireless ECG monitoring and 24/7/365 analysis and response.
A surgeon and an electrophysiologist in the Methodist DeBakey Heart & Vascular Center last week worked together to perform a novel, minimally-invasive procedure to treat a common but dangerous arrhythmia in a 61-year-old lawyer from east Texas who has suffered from the condition for months.
St. Jude Medical, Inc. today announced it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin enrollment in the IRASE AF (IRrigated Ablation System Evaluation for AF) trial, a multicenter, randomized, single-blind study evaluating the safety and efficacy of the company’s Duo 12 port open irrigated catheter ablation system for treatment of Atrial Fibrillation (AF). AF is the most common cardiac arrhythmia (abnormal heartbeat), affecting an estimated 3.3 million Americans and millions more worldwide.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.